格隆汇1月24日丨康哲药业(00867.HK)公告,于2025年1月24日,集团通过公司附属公司与湖南麦济生物技术股份有限公司(麦济生物)及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10(MG-K10或产品)签订合作协议。根据协议,集团获得产品在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及新加坡的协议所约定的共同开发权及独家商业化权利;麦济生物配合商业化活动,并销售、供应...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.